Prescription drug television advertising took off 18 years ago when FDA issued final guidance that required broadcast ads to only disclose a product's major risks. The agency is now considering further limiting the disclosure to risks that are severe, serious, or actionable.
Less Is More: FDA May Narrow Risk Info In Rx Drug TV Ads
Agency is considering whether drug broadcast ads should note only risks that are severe, serious or actionable; FDA study finds this limitation improves risk recall and recognition of benefits.
